CN1514835A - 苯并氧杂吖庚因衍生物和它们作为ampa受体刺激物的应用 - Google Patents
苯并氧杂吖庚因衍生物和它们作为ampa受体刺激物的应用 Download PDFInfo
- Publication number
- CN1514835A CN1514835A CNA028116410A CN02811641A CN1514835A CN 1514835 A CN1514835 A CN 1514835A CN A028116410 A CNA028116410 A CN A028116410A CN 02811641 A CN02811641 A CN 02811641A CN 1514835 A CN1514835 A CN 1514835A
- Authority
- CN
- China
- Prior art keywords
- benzoxazepine
- alkyl
- formula
- compound
- ketone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
化合物 | 10μM下的稳态电流增加% |
(S)-2,3,11,11a-四氢-1H,5H-吡咯并[2,1-c][1,4]苯并氧杂吖庚因-5-酮* | 53 |
(R)-2,3,11,11a-四氢-1H,5H-吡咯并[2,1-c][1,4]苯并氧杂吖庚因-5-酮 | 24 |
(R)-7-氟-2,3,11,11a-四氢-1H,5H-吡咯并[2,1-c][1,4]-苯并氧杂吖庚因-5-酮(实施例 1) | 17 |
(S)-7-氟-2,3,11,11a-四氢-1H,5H-吡咯并[2,1-c][1,4]-苯并氧杂吖庚因-5-酮(实施例 2) | 19 |
(R)-9-氟-2,3,11,11a-四氢-1H,5H-吡咯并[2,1-c][1,4]-苯并氧杂吖庚因-5-酮(实施例 3A) | 23 |
(S)-9-氟-2,3,11,11a-四氢-1H,5H-吡咯并[2,1-c][1,4]-苯并氧杂吖庚因-5-酮(实施例 3B) | 20 |
(S)-2,3,11,11a-四氢-1H,5H-吡咯并[2,1-c][5,1,4]苯并硫杂氧杂吖庚因-5-二氧化物(实施例 10) | 7 |
(S)-8-甲氧基-2,3,11,11a-四氢-1H,5H-吡咯并[2,1-c][1,4]苯并氧杂吖庚因-5-酮(实施例 11) | 21 |
(S)-N-(2,3,11,11a-四氢-5-氧代-1H,5H-吡咯并[2,1-a][1,4]苯并氧杂吖庚因-7-基)乙酰胺(实施例 14) | 49 |
(S)-7-(吗啉羰基)-2,3,11,11a-四氢-1H,5H-吡咯并[2,1-c][1,4]苯并氧杂吖庚因-5-酮(实施例 16A) | 24 |
(R)-7-(氨基羰基)-2,3,11,11a-四氢-1H,5H-吡咯并[2,1-c][1,4]苯并氧杂吖庚因-5-酮(实施例 17A) | 8 |
(11,11aS)-11-乙基-2,3,11,11a-四氢-1H,5H-吡咯并[2,1-c][1,4]苯并氧杂吖庚因-5-酮(实施例 20A) | 31 |
(11S,11aS)-11-乙基-2,3,11,11a-四氢-1H,5H-吡咯并[2,1-c][1,4]苯并氧杂吖庚因-5-酮(实施例 20B) | 28 |
6,6a-二氢-12H-吗啉并[3,4-c][1,4]苯并氧杂吖庚因-12-酮(实施例 22) | 31 |
(S)-1,2,10,10a-四氢氮杂环丁基[2,1-c][1,4]苯并氧杂吖庚因-4-酮(实施例 23) | 16 |
2,11,11a-三氢-3,3-二甲基噁唑烷基[2,1-c][1,4]-苯并氧杂吖庚因-5-酮(实施例 24) | 18 |
(2R,11aS)-2-羟基-2,3,11,11a-四氢-1H,5H-吡咯并[2,1-c][1,4]苯并氧杂吖庚因-5-酮(实施例 25) | 31 |
(2S,11aS)-2-氟-2,3,1,11a-四氢-1H,5H-吡咯并[2,1-c][1,4]苯并氧杂吖庚因-5-酮(实施例 26) | 24 |
(2S,11aS)-2,2-二氟-2,3,11,11a-四氢-1H,5H-吡咯并[2,1-c][1,4]苯并氧杂吖庚因-5-酮(实施例 28) | 9 |
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01202215 | 2001-06-11 | ||
EP01202215.8 | 2001-06-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1514835A true CN1514835A (zh) | 2004-07-21 |
CN1257908C CN1257908C (zh) | 2006-05-31 |
Family
ID=8180450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB028116410A Expired - Lifetime CN1257908C (zh) | 2001-06-11 | 2002-06-05 | 苯并氧杂吖庚因衍生物和它们作为ampa受体刺激物的应用 |
Country Status (30)
Country | Link |
---|---|
US (2) | US7307073B2 (zh) |
EP (1) | EP1399450B1 (zh) |
JP (1) | JP4435561B2 (zh) |
KR (1) | KR100863255B1 (zh) |
CN (1) | CN1257908C (zh) |
AR (1) | AR036092A1 (zh) |
AT (1) | ATE389659T1 (zh) |
AU (1) | AU2002314144B2 (zh) |
BR (1) | BR0210222A (zh) |
CA (1) | CA2450274C (zh) |
CO (1) | CO5550447A2 (zh) |
CZ (1) | CZ300052B6 (zh) |
DE (1) | DE60225689T2 (zh) |
EC (1) | ECSP034891A (zh) |
ES (1) | ES2301651T3 (zh) |
HK (1) | HK1061858A1 (zh) |
HR (1) | HRP20031007A2 (zh) |
HU (1) | HUP0400154A3 (zh) |
IL (2) | IL158905A0 (zh) |
IS (1) | IS2526B (zh) |
MX (1) | MXPA03011563A (zh) |
NO (1) | NO328705B1 (zh) |
NZ (1) | NZ529670A (zh) |
PE (1) | PE20030097A1 (zh) |
PL (1) | PL366721A1 (zh) |
RU (1) | RU2279434C2 (zh) |
SK (1) | SK287150B6 (zh) |
TW (1) | TWI232863B (zh) |
WO (1) | WO2002100865A1 (zh) |
ZA (1) | ZA200309382B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103153973A (zh) * | 2010-09-16 | 2013-06-12 | 瑟维尔实验室 | 二氢苯并氧硫氮杂*衍生物、其制备方法、包含此类化合物的药用组合物以及它们作为ampa受体调节剂的用途 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100864267B1 (ko) | 2001-06-14 | 2008-10-20 | 엔.브이.오가논 | AMPA 수용체의 양성 조절제로서의(피리도/티에노)-[f]-옥사제핀-5-온 유도체 |
US20110218190A1 (en) * | 2008-11-10 | 2011-09-08 | The Regents Of The University Of California | Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction |
ES2444779T3 (es) * | 2009-09-28 | 2014-02-26 | F. Hoffmann-La Roche Ag | Compuestos de benzoxazepina inhibidores de la PI3K y su utilización en el tratamiento de cáncer |
CA2915405A1 (en) | 2013-06-13 | 2014-12-18 | Veroscience Llc | Compositions and methods for treating metabolic disorders |
AU2017353986B2 (en) | 2016-11-07 | 2021-08-19 | Arbutus Biopharma Corporation | Substituted pyridinone-containing tricyclic compounds, and methods using same |
TWI801517B (zh) | 2018-03-12 | 2023-05-11 | 加拿大商愛彼特生物製藥公司 | 經取代的2-吡啶酮三環化合物、其類似物及其使用方法 |
TW202010499A (zh) | 2018-04-12 | 2020-03-16 | 加拿大商愛彼特生物製藥公司 | 經取代的吡啶酮之三環化合物的製備方法 |
EP4121072A1 (en) * | 2020-03-20 | 2023-01-25 | Amathus Therapeutics, Inc. | Cyclic sulfonamide derivatives as trap1 modulators and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1238719A (zh) | 1968-11-01 | 1971-07-07 | ||
ATE215079T1 (de) | 1992-07-24 | 2002-04-15 | Univ California | Arzneimittel, die den durch ampa rezeptoren vermittelten synaptischen respons erhöhen |
US6174881B1 (en) | 1995-01-06 | 2001-01-16 | Hoffman-La Roche Inc. | Hydroxymethylimidazodiazepines and their esters |
US5650409A (en) * | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
US5736543A (en) * | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
DE69831446T2 (de) | 1997-06-09 | 2006-06-14 | Pfizer Prod Inc | Chinazolin-4-on AMPA Antagonisten |
US5985871A (en) * | 1997-12-24 | 1999-11-16 | Cortex Pharmaceuticals, Inc. | Benzoxazine compounds for enhancing synaptic response |
EP1071426A2 (en) * | 1998-02-18 | 2001-01-31 | Neurosearch A/S | Novel compounds and their use as positive ampa receptor modulators |
US6124278A (en) | 1998-04-03 | 2000-09-26 | The Regents Of The University Of California | Acylbenzoxazines for enhancing synaptic response |
-
2002
- 2002-05-31 TW TW091111746A patent/TWI232863B/zh not_active IP Right Cessation
- 2002-06-05 CN CNB028116410A patent/CN1257908C/zh not_active Expired - Lifetime
- 2002-06-05 KR KR1020037016150A patent/KR100863255B1/ko not_active IP Right Cessation
- 2002-06-05 DE DE60225689T patent/DE60225689T2/de not_active Expired - Lifetime
- 2002-06-05 AT AT02740691T patent/ATE389659T1/de active
- 2002-06-05 CA CA2450274A patent/CA2450274C/en not_active Expired - Lifetime
- 2002-06-05 RU RU2004100310/04A patent/RU2279434C2/ru not_active IP Right Cessation
- 2002-06-05 US US10/480,623 patent/US7307073B2/en not_active Expired - Lifetime
- 2002-06-05 JP JP2003503632A patent/JP4435561B2/ja not_active Expired - Lifetime
- 2002-06-05 EP EP02740691A patent/EP1399450B1/en not_active Expired - Lifetime
- 2002-06-05 IL IL15890502A patent/IL158905A0/xx unknown
- 2002-06-05 PL PL02366721A patent/PL366721A1/xx not_active IP Right Cessation
- 2002-06-05 NZ NZ529670A patent/NZ529670A/en unknown
- 2002-06-05 BR BR0210222-6A patent/BR0210222A/pt not_active Application Discontinuation
- 2002-06-05 CZ CZ20033376A patent/CZ300052B6/cs not_active IP Right Cessation
- 2002-06-05 MX MXPA03011563A patent/MXPA03011563A/es active IP Right Grant
- 2002-06-05 ES ES02740691T patent/ES2301651T3/es not_active Expired - Lifetime
- 2002-06-05 SK SK1518-2003A patent/SK287150B6/sk not_active IP Right Cessation
- 2002-06-05 HU HU0400154A patent/HUP0400154A3/hu unknown
- 2002-06-05 WO PCT/EP2002/006185 patent/WO2002100865A1/en active IP Right Grant
- 2002-06-05 AU AU2002314144A patent/AU2002314144B2/en not_active Expired
- 2002-06-10 PE PE2002000495A patent/PE20030097A1/es not_active Application Discontinuation
- 2002-06-10 AR ARP020102171A patent/AR036092A1/es unknown
-
2003
- 2003-11-13 IS IS7036A patent/IS2526B/is unknown
- 2003-11-17 IL IL158905A patent/IL158905A/en not_active IP Right Cessation
- 2003-12-02 ZA ZA200309382A patent/ZA200309382B/en unknown
- 2003-12-04 CO CO03107046A patent/CO5550447A2/es not_active Application Discontinuation
- 2003-12-04 HR HR20031007A patent/HRP20031007A2/xx not_active Application Discontinuation
- 2003-12-10 NO NO20035486A patent/NO328705B1/no not_active IP Right Cessation
- 2003-12-11 EC EC2003004891A patent/ECSP034891A/es unknown
-
2004
- 2004-07-07 HK HK04104926A patent/HK1061858A1/xx not_active IP Right Cessation
-
2007
- 2007-10-25 US US11/924,451 patent/US7504390B2/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103153973A (zh) * | 2010-09-16 | 2013-06-12 | 瑟维尔实验室 | 二氢苯并氧硫氮杂*衍生物、其制备方法、包含此类化合物的药用组合物以及它们作为ampa受体调节剂的用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2488524B1 (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
CN1191232C (zh) | 氨甲基羧酸衍生物 | |
CN105008362B (zh) | 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3‑d]嘧啶衍生物 | |
JP2022523774A (ja) | 脳障害を治療するためのn-置換インドール及び他の複素環化合物 | |
CN1257908C (zh) | 苯并氧杂吖庚因衍生物和它们作为ampa受体刺激物的应用 | |
CA2402751C (en) | Decahydro-isoquinolines | |
JP2017048212A (ja) | Bace阻害剤 | |
KR20150042269A (ko) | N형 칼슘 채널 차단제로서의 치환된 피라졸 | |
KR20170141768A (ko) | 이미다조피라진 및 피라졸로피리미딘 및 ampa 수용체 조절제로서의 이의 용도 | |
AU2014281032A1 (en) | Bace inhibitors | |
EP1907372A1 (en) | Substituted cyclohexyl derivatives as nk-3 receptor antagonists | |
JP2014516084A (ja) | 新規化合物 | |
JP2019532981A (ja) | 融合アザヘテロ環状化合物、及びampa受容体調節因子としてのそれらの使用 | |
CN1255413C (zh) | 作为ampa受体正性调节剂的(吡啶并/噻吩并)-[f]-氧杂吖庚因-5-酮衍生物 | |
EP4267555A1 (en) | Octahydroisoquinolinyl derivatives | |
JP2023528280A (ja) | 例えば、うつ病を治療するための、gpr139拮抗薬としての1-((1h-ピラゾール-4-イル)メチル)-3-(フェニル)-1,3-ジヒドロ-2h-イミダゾール-2-オン誘導体および関連化合物 | |
EP2941427B1 (fr) | Nouveaux dérivés benzodioxane-piperidine et leurs applications thérapeutiques pour le traitement des affections neuropsychiatriques | |
KR20170043581A (ko) | 2,2,2-트라이플루오로에틸-티아다이아진 | |
CN118265710A (zh) | 吡啶化合物作为kv7.2增强剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ORGANON NV Free format text: FORMER OWNER: AKZO NOVEL N.V. CORP. Effective date: 20070105 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20070105 Address after: Holland Patentee after: N.V. ORGANON Address before: Holland Arnhem Patentee before: AKZO NOBEL N.V. |
|
C56 | Change in the name or address of the patentee |
Owner name: MSD OUSI CO., LTD. Free format text: FORMER NAME: ORGANON NV |
|
CP01 | Change in the name or title of a patent holder |
Address after: Holland Patentee after: N.V. Organon Address before: Holland Patentee before: N.V. ORGANON |
|
ASS | Succession or assignment of patent right |
Owner name: MERCK SHARP + DOHME CORP. Free format text: FORMER OWNER: ORGANON BIOLOGICAL NETHERLANDS CO., LTD. Effective date: 20131010 Owner name: ORGANON BIOLOGICAL NETHERLANDS CO., LTD. Free format text: FORMER OWNER: MSD OUSI CO., LTD. Effective date: 20131010 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20131010 Address after: Haarlem Patentee after: MERCK SHARP & DOHME B.V. Address before: Haarlem Patentee before: Organon biological science Holland Co.,Ltd. Effective date of registration: 20131010 Address after: Haarlem Patentee after: Organon biological science Holland Co.,Ltd. Address before: Holland Patentee before: N.V. Organon |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060531 |